Prothena Target of Unusually Large Options Trading (PRTA)

Prothena Corp (NASDAQ:PRTA) was the recipient of unusually large options trading on Thursday. Stock traders bought 2,176 put options on the stock. This is an increase of 1,360% compared to the typical volume of 149 put options.

Several research analysts have recently commented on PRTA shares. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 price target on shares of Prothena in a research report on Sunday, February 4th. Deutsche Bank reissued a “buy” rating on shares of Prothena in a research report on Wednesday, March 21st. ValuEngine lowered Prothena from a “hold” rating to a “sell” rating in a research report on Friday, December 15th. BidaskClub lowered Prothena from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 8th. Finally, Zacks Investment Research lowered Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Prothena presently has an average rating of “Buy” and a consensus price target of $72.83.

How to Become a New Pot Stock Millionaire

A number of large investors have recently made changes to their positions in the stock. Woodford Investment Management Ltd increased its position in Prothena by 1.6% during the 4th quarter. Woodford Investment Management Ltd now owns 11,528,614 shares of the biotechnology company’s stock valued at $325,223,000 after buying an additional 179,000 shares in the last quarter. Alliancebernstein L.P. increased its position in Prothena by 11.2% during the 4th quarter. Alliancebernstein L.P. now owns 1,005,998 shares of the biotechnology company’s stock valued at $37,715,000 after buying an additional 101,273 shares in the last quarter. Jennison Associates LLC increased its position in Prothena by 1.3% during the 4th quarter. Jennison Associates LLC now owns 416,031 shares of the biotechnology company’s stock valued at $15,597,000 after buying an additional 5,313 shares in the last quarter. Deutsche Bank AG increased its position in Prothena by 37.8% during the 4th quarter. Deutsche Bank AG now owns 231,468 shares of the biotechnology company’s stock valued at $8,674,000 after buying an additional 63,537 shares in the last quarter. Finally, Hood River Capital Management LLC increased its position in Prothena by 7.5% during the 4th quarter. Hood River Capital Management LLC now owns 213,119 shares of the biotechnology company’s stock valued at $7,990,000 after buying an additional 14,843 shares in the last quarter.

PRTA opened at $39.51 on Friday. The firm has a market capitalization of $1,704.93, a PE ratio of -9.71 and a beta of 2.70. Prothena has a 12 month low of $27.19 and a 12 month high of $70.00.

Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.48) by $0.24. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.27 million. During the same period in the prior year, the company posted ($1.41) EPS. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. research analysts anticipate that Prothena will post -5.34 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3336715/prothena-target-of-unusually-large-options-trading-prta.html.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Credits  Price Up 13.7% This Week
Credits Price Up 13.7% This Week
Apex  Price Hits $0.22 on Major Exchanges
Apex Price Hits $0.22 on Major Exchanges
Scry.info  24-Hour Volume Hits $849,453.00
Scry.info 24-Hour Volume Hits $849,453.00
Zacks: Analysts Expect Kinsale Capital Group  Will Post Quarterly Sales of $50.93 Million
Zacks: Analysts Expect Kinsale Capital Group Will Post Quarterly Sales of $50.93 Million
Brokerages Expect MB Financial Inc.  Will Announce Quarterly Sales of $247.80 Million
Brokerages Expect MB Financial Inc. Will Announce Quarterly Sales of $247.80 Million
RPC, Inc.  Expected to Announce Earnings of $0.28 Per Share
RPC, Inc. Expected to Announce Earnings of $0.28 Per Share


© 2006-2018 Ticker Report. Google+.